Omnicell (OMCL) announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. In this newly created position, Couldry will serve as Omnicell’s senior clinical authority focused on bringing the perspective and voice of health system pharmacy leaders to the Company’s innovation roadmap and portfolio decisions. Prior to joining Omnicell, Couldry served as Vice President of Pharmacy and Health Professions at The University of Kansas Health System.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell price target raised to $70 from $60 at KeyBanc
- Analyst Reiterates Buy on Omnicell, Citing Once-in-a-Decade Product Cycle Momentum and Margin Strength; Price Target Maintained at $70
- Omnicell Earnings Call Shows Profits Surging, Outlook Raised
- Omnicell reports Q1 adjusted EPS 55c, consensus 33c
- Omnicell sees Q2 adjusted EPS 40c-48c, consensus 42c